Reduction in Corrected SUVmax of Primary Malignancy After Neoadjuvant Therapy
| Patients with reduction to background level | Percentage of reduction | ||||
| Tumor characteristic | No. of patients | n | % | Median | Range |
| Histology | |||||
| IDC | 18 | 10 | 55.6 | 100.0 | 100.0–38.7 |
| ILC | 6 | 2 | 33.3 | 70.0 | 100.0–32.8 |
| Receptor status | |||||
| ER+/HER2− | 11 | 4 | 36.4 | 74.1 | 100.0–32.8 |
| HER2+ | 7 | 5 | 71.4 | 100.0 | 100.0–44.7 |
| Triple negative | 6 | 3 | 50 | 98.8 | 100.0–67.4 |
| Histologic grade | |||||
| 1 or 2 | 9 | 3 | 33.3 | 74.1 | 100.0–32.8 |
| 3 | 15 | 9 | 60 | 100.0 | 100.0–38.7 |